NCT02116543View on ClinicalTrials.gov

TD-6450 MAD Study in HCV Infected Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Hepatitis CHCV
Interventions
DRUG

TD-6450

DRUG

Placebo

Trial Locations (1)

78215

Texas Liver Institute, San Antonio

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT02116543 - TD-6450 MAD Study in HCV Infected Subjects | Biotech Hunter | Biotech Hunter